KDR and neoplasm: LNP-CAD9 co-delivering Cas9 mRNA and VEGFR2 sgRNA demonstrated remarkable in vivo antitumor therapy, as evidenced by a significant reduction in VEGFR2 levels, decreased tumor area per lung, prolonged survival, and a marked decrease in microvascular density within the tumor area, outperforming gold-standard MC3/DOTAP LNPs.